IMMUNE THERAPEUTICS LABELED AS A PIONEER IN FORBES ARTICLE DISCUSSING BOOMING PET CARE INDUSTRY
September 05 2018 - 11:15AM
InvestorsHub NewsWire
IMMUNE THERAPEUTICS LABELED AS A PIONEER IN
FORBES ARTICLE DISCUSSING BOOMING PET CARE
INDUSTRY
Orlando, FL -- September 5, 2018 --
InvestorsHub NewsWire -- Immune Therapeutics, Inc. (OTCQB:
IMUN), a late-stage biopharmaceutical company focused on the
development of therapies for the
treatment of autoimmune diseases, inflammatory diseases, cancer and
HIV/AIDS, today announced that the Company’s multi-pronged growth
strategy, which includes the pursuit of the multi-billion dollar
pet care industry, was favorably mentioned in an article published
today in Forbes Magazine. (Link to Story: Can Cats and Dogs Help Reverse Marijuana’s
Stigma?)
The article,
which also includes excerpts from an interview with the Company’s
CEO, Noreen Griffin, classifies Immune Therapeutics as a
‘pioneering biopharmaceutical company that recognized the massive
potential in the growing animal health market and has introduced a
partnership to tap into it’ (referring to the Company’s recent 10%
acquisition of Cytocom, Inc. which included exclusive rights to
Lodonal™ and Met-Enkephline for the treatment of pets in the United
States).
“Today’s positive
coverage of Immune Therapeutics by such a well-respected and
internationally distributed publication, such as Forbes, is a yet
another indication that Immune has truly embarked on a new era of
growth and expansion as we look towards the bright future that lays
ahead,” said Ms. Griffin. “We believe the ongoing progress we are
making in Africa, along with the recent filings of new patents and
the exclusive revenue channels stemming from the pet care industry
will further strengthen Immune Therapeutics, Inc.’s market
position,” concluded Ms. Griffin.
Immune Therapeutics Gains Exclusive Drug Rights for
Booming Pet Care Industry
The
global market for animal medication is projected to reach $44.4
billion by 2022, driven by increasing investments in animal drug
development in response to unmet animal health needs and
developments in veterinary diagnostics and services. Overall, 68%
of U.S. households, or about 84.6 million homes, own a pet,
according to the APPA. Dogs and cats are the most popular pets,
followed by freshwater fish and birds.
ABOUT IMMUNE THERAPEUTICS,
INC.
Immune Therapeutics, Inc. is a
late-stage biopharmaceutical company focused on the development and
commercialization of highly innovative immunotherapies. Immune
Therapeutics is actively developing T-Activation immunotherapies to
achieve immunomodulation in patients both human and pets with
autoimmune and inflammatory disease, cancer and infectious
diseases.
Forward-Looking
Statements
This release may contain
forward-looking statements. Actual results may differ from those
projected due to a number of risks and uncertainties, including,
but not limited to, the possibility that some or all the matters
and transactions considered by the Company may not proceed as
contemplated, and by all other matters specified in the Company’s
filings with the Securities and Exchange Commission. These
statements are made based upon current expectations that are
subject to risk and uncertainty. The Company does not undertake to
update forward-looking statements in this news release to reflect
actual results, changes in assumptions or changes in other factors
affecting such forward-looking information. Assumptions and other
information that could cause results to differ from those set forth
in the forward-looking information can be found in the Company’s
filings with the Securities and Exchange Commission (www.sec.gov),
including its recent periodic reports.
888-613-8802
http://www.immunetherapeutics.com/
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Apr 2023 to Apr 2024